Established and experimental medical therapy of pulmonary sarcoidosis

European Respiratory Journal

Volumn 41, Issue 6, 2013, Pages 1424-1438

  Baughman, Robert P ^a   Nunes, Hilario ^b   Sweiss, Nadera J ^c   Lower, Elyse E ^a,d  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b AVICENNE HOSPITAL   (France)

^c UNIVERSITY OF ILLINOIS   (United States)

^d Oncology Hematology Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; APRELIMAST; APREMILAST; AZATHIOPRINE; BIOLOGICAL PRODUCT; BUDESONIDE; CHLOROQUINE; CYCLOSPORIN A; CYTOTOXIC AGENT; ETANERCEPT; FLUTICASONE; FOLIC ACID; GLUCOCORTICOID; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VASOACTIVE INTESTINAL POLYPEPTIDE; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

ALLERGIC PNEUMONITIS; CLINICAL ASSESSMENT; CONSTIPATION; COUGHING; CREUTZFELDT JAKOB DISEASE; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EYE TOXICITY; FORCED VITAL CAPACITY; GASTROINTESTINAL TOXICITY; HEPATITIS B; HUMAN; HYPERSOMNIA; HYPERTENSION; INFECTION; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; LUNG FUNCTION; LUNG SARCOIDOSIS; LUNG TOXICITY; LUPUS LIKE SYNDROME; MALIGNANT NEOPLASTIC DISEASE; MOUTH DISEASE; MOUTH SORE; NAUSEA; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SARCOIDOSIS; SIDE EFFECT; THORAX RADIOGRAPHY; TOXIC HEPATITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; WEIGHT GAIN; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DYSPNEA; EXPERIMENTAL THERAPY; LUNG FUNCTION TEST; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; SARCOIDOSIS, PULMONARY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; CLINICAL TRIALS AS TOPIC; DYSPNEA; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; METHOTREXATE; POSITRON-EMISSION TOMOGRAPHY; QUALITY OF LIFE; RADIOGRAPHY, THORACIC; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS, PULMONARY; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 84878779658     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00060612     Document Type: Review

References (165)

1. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63: Suppl. 5, v1-v58.
2. Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol 2012; 8: 95-103.
3. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287: 1301-1307. (Pubitemid 34250485)
4. Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2003; CD003536.
5. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med 2010; 31: 409-418.
6. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J 1961; 2: 1165-1172.
7. Muers MF, Middleton WG, Gibson GJ, et al. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society study of longterm corticosteroid treatment. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14: 46-56. (Pubitemid 27170555)
8. Baughman RP, Shipley R, Desai S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2009; 136: 526-535.
9. Zappala CJ, Desai SR, Copley SJ, et al. Optimal scoring of serial change on chest radiography in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 130-138.
10. Keijsers RG, Verzijlbergen JF, van Diepen DM, et al. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 143-149.
11. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-1953.
12. Cox CE, Donohue JF, Brown CD, et al. The sarcoidosis health questionnaire. A new measure of health-related quality of life. Am J Resp Crit Care Med 2003; 168: 323-329. (Pubitemid 36969884)
13. de Vries J, Michielsen H, van Heck GL, et al. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9: 279-291. (Pubitemid 39277403)
14. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51: 238-247.
15. Park MK, Fontana JR, Babaali H, et al. Steroid sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 121-131.
16. Pietinalho A, Tukiainen P, Haahtela T, et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study. Chest 1999; 116: 424-431. (Pubitemid 29382128)
17. Spratling L, Tenholder MF, Underwood GH, et al. Daily vs alternate day prednisone therapy for stage II sarcoidosis. Chest 1985; 88: 687-690.
18. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 198-204.
19. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
20. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-66. (Pubitemid 30157757)
21. Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-1122.
22. Wyser CP, van Schalkwyk EM, Alheit B, et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med 1997; 156: 1371-1376. (Pubitemid 27505496)
23. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160: 192-197. (Pubitemid 29326087)
24. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-1669. (Pubitemid 27216674)
25. Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-1150.
26. Judson MA, Silvestri J, Hartung C, et al. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 51-57. (Pubitemid 44259209)
27. Prasse A, Zissel G, Lützen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010; 182: 540-548.
28. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802. (Pubitemid 44511661)
29. Sweiss NJ, Barnathan ES, Lo K, et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 49-56.
30. Rossman MD, Newman LS, Baughman RP, et al. A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-208. (Pubitemid 47596315)
31. McKinzie BP, Bullington WM, Mazur JE, et al. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010; 339: 1-4.
32. Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973; 107: 609-614.
33. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008; 29: 533-548. (Pubitemid 351784486)
34. Loza MJ, Brodmerkel C, du Bois RM, et al. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol 2011; 18: 931-939.
35. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-836.
36. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
37. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
38. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155: 846-851.
39. Sharma OP, Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest 1988; 94: 343-346.
40. Lavergne F, Clerici C, Sadoun D, et al. Airway obstruction in bronchial sarcoidosis: outcome with treatment. Chest 1999; 116: 1194-1199. (Pubitemid 29535968)
41. Chambellan A, Turbie P, Nunes H, et al. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest 2005; 127: 472-481. (Pubitemid 40229305)
42. Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. Scand J Respir Dis 1979; 60: 215-221.
43. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128: 1483-1489. (Pubitemid 41324436)
44. Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 108-116. (Pubitemid 47471829)
45. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132: 207-213. (Pubitemid 47068223)
46. Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 1150-1157. (Pubitemid 40663728)
47. Baughman RP, Lower EE. Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med 2007; 13: 439-444. (Pubitemid 47472308)
48. Judson MA, Highland KB, Kwon S, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 139-145.
49. Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 110-120.
50. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis associated fatigue. Chest 2008; 133: 1189-1195. (Pubitemid 351685525)
51. DeRemee RA. The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives. Chest 1983; 83: 128-133. (Pubitemid 13172764)
52. Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 147-153. (Pubitemid 41020022)
53. McLoud TC, Epler GR, Gaensler EA, et al. A radiographic classification for sarcoidosis: physiologic correlation. Invest Radiol 1982; 17: 129-138. (Pubitemid 12161701)
54. Welch LS, Hunting KL, Balmes J, et al. Variability in the classification of radiographs using the 1980 International Labor Organization Classification for Pneumoconioses. Chest 1998; 114: 1740-1748. (Pubitemid 128487497)
55. Judson MA, Gilbert GE, Rodgers JK, et al. The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis. Respirology 2008; 13: 97-102.
56. Oberstein A, von Zitzewitz H, Schweden F, et al. Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14: 65-72. (Pubitemid 27170557)
57. Hansell DM, Milne DG, Wilsher ML, et al. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thinsection CT. Radiology 1998; 209: 697-704. (Pubitemid 28564901)
58. Milman N, Graudal N, Loft A, et al. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 2012; 6: 238-247.
59. Baughman RP, Shipley R, Eisentrout CE. Predictive value of gallium scan, angiotensin-converting enzyme level, and broncho-alveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung 1987; 165: 371-377. (Pubitemid 17165347)
60. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586. (Pubitemid 29296676)
61. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-381. (Pubitemid 13215050)
62. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758. (Pubitemid 14121920)
63. de Kleijn WP, de Vries J, Lower EE, et al. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15: 499-506.
64. DeRemee RA, Rohrbach MS. Serum angiotensin-converting enzyme in evaluating the clinical course of sarcoidosis. Ann Intern Med 1980; 92: 361-365. (Pubitemid 10154811)
65. Baughman RP, Ploysongsang Y, Roberts RD, et al. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis 1983; 128: 631-633. (Pubitemid 13014110)
66. Grönhagen-Riska C, Selroos O, Niemisto M. Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid- treated sarcoidosis. Eur J Respir Dis 1980; 61: 113-122. (Pubitemid 10122697)
67. Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med 2008; 29: 445-458. (Pubitemid 351778212)
68. Bargagli E, Maggiorelli C, Rottoli P. Human chitotriosidase: a potential new marker of sarcoidosis severity. Respiration 2008; 76: 234-238.
69. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990; 142: 1268-1271.
70. Pinkston P, Saltini C, Muller-Quernheim J, et al. Corticosteroid therapy suppresses spontaneous interleukin 2 release and spontaneous proliferation of lung T lymphocytes of patients with active pulmonary sarcoidosis. J Immunol 1987; 139: 755-760. (Pubitemid 17107072)
71. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 2006; 129: 174-181. (Pubitemid 43265259)
72. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183: 573-581.
73. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/ WASOG statement on sarcoidosis. American Thoracic Society/ European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-173.
74. Palmero V, Sulica R. Sarcoidosis-associated pulmonary hypertension: assessment and management. Semin Respir Crit Care Med 2010; 31: 494-500.
75. Johns CJ, Michele TM. The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins hospital. Medicine 1999; 78: 65-111. (Pubitemid 29153026)
76. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-631. (Pubitemid 27132936)
77. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999; 115: 1158-1165. (Pubitemid 29193691)
78. James DG, Carstairs LS, Trowell J, et al. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet 1967; 2: 526-528.
79. Harkleroad LE, Young RL, Savage PJ, et al. Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy. Chest 1982; 82: 84-87. (Pubitemid 12037771)
80. Mikami R, Hiraga Y, Iwai K, et al. A double-blind controlled trial on the effect of corticosteroid therapy in sarcoidosis. In: Iwai K, Hosoda Y, eds. Proceedings of the VI International Conference on Sarcoidosis. Tokyo, University of Tokyo Press, 1974; pp. 533-538.
81. Zaki MH, Lyons HA, Leilop L, et al. Corticosteroid therapy in sarcoidosis: a five year controlled follow-up. NY State J Med 1987; 87: 496-499. (Pubitemid 18007689)
82. du Bois RM, Greenhalgh PM, Southcott AM, et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13: 1345-1350. (Pubitemid 29357151)
83. Milman N, Graudal N, Grode G, et al. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236: 285-290. (Pubitemid 24283067)
84. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995; 8: 682-688.
85. Selroos O, Löfroos AB, Pietinalho A, et al. Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1994; 11: 126-131. (Pubitemid 24311242)
86. Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993; 10: 56-61. (Pubitemid 23140876)
87. Pietinalho A, Tukiainen P, Haahtela T, et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121: 24-31. (Pubitemid 34114224)
88. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002; 8: 470-476. (Pubitemid 34836955)
89. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis 1997; 14: 121-130. (Pubitemid 27427344)
90. Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 87-92. (Pubitemid 29164275)
91. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 43-48. (Pubitemid 38533813)
92. Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250: 713-720.
93. Kamphuis LS, Lam-Tse WK, Dik WA, et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011; 184: 1214-1216.
94. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-185. (Pubitemid 36851350)
95. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122: 227-232. (Pubitemid 34754167)
96. Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299: 153-157. (Pubitemid 20085232)
97. Gedalia A, Molina JF, Ellis GS, et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr 1997; 130: 25-29. (Pubitemid 27492715)
98. Israel HL. The treatment of sarcoidosis. Postgrad Med J 1970; 46: 537-540.
99. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833-841.
100. Morgan SL, Baggott JE. Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: Suppl. 61, S102-S109.
101. Zisman DA, McCune WJ, Tino G, et al. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 243-252. (Pubitemid 32896349)
102. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000; 15: 373-381. (Pubitemid 30085968)
103. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829-1837. (Pubitemid 27452534)
104. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987; 14: 1164-1171. (Pubitemid 18049936)
105. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655-665.
106. Kremer JM, Alarcón GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 316-328. (Pubitemid 24093622)
107. Baughman RP, Koehler A, Bejarano PA, et al. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med 2003; 163: 615-620. (Pubitemid 36314350)
108. Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyltranferase testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 2010; 188: 125-132.
109. Romagnuolo J, Sadowski DC, Lalor E, et al. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998; 12: 479-483. (Pubitemid 28495463)
110. Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003; CD002047.
111. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-733. (Pubitemid 35265316)
112. Jenks KA, Stamp LK, O'Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol 2007; 34: 2201-2203. (Pubitemid 350076879)
113. Martin K, Bentaberry F, Dumoulin C, et al. Neuropathy associated with leflunomide: a case series. Ann Rheum Dis 2005; 64: 649-650. (Pubitemid 40469104)
114. Savage RL, Highton J, Boyd IW, et al. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006; 36: 162-169.
115. Cannon GW, Holden WL, Juhaeri J, et al. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol 2004; 31: 1906-1911. (Pubitemid 39341199)
116. Sawada T, Inokuma S, Sato T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1069-1072.
117. Sato T, Inokuma S, Sagawa A, et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1265-1268.
118. Ziegenhagen MW, Rothe ME, Zissel G, et al. Exagerated TNFalpha release of alveolar macrophages in corticosteroid resistent sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 185-190.
119. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 76-89.
120. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-74. (Pubitemid 32280539)
121. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127: 1064-1071. (Pubitemid 40775543)
122. Saleh S, Ghodsian S, Yakimova V, et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006; 100: 2053-2059. (Pubitemid 44514944)
123. Baughman RP. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de Pneumonologia 2007; 13: S47-S50.
124. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239. (Pubitemid 47300424)
125. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838. (Pubitemid 351650483)
126. Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303-1308.
127. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003; 30: 1864-1867. (Pubitemid 36962468)
128. Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128: 1062-1067. (Pubitemid 41140552)
129. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094. (Pubitemid 33022088)
130. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010; 30: 339-353.
131. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-251. (Pubitemid 47067483)
132. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
133. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-528.
134. Gómez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761. (Pubitemid 46932080)
135. Matulis G, Jüni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen specific interferon gamma assay. Ann Rheum Dis 2008; 67: 84-90.
136. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-346.
137. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-3140. (Pubitemid 36793081)
138. Felekis T, Katsanos K, Christodoulou D, et al. Reversible bilateral optic neuritis after infliximab discontinuation in a patient with Crohn's disease. J Crohns Colitis 2009; 3: 212-214.
139. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6: 1212-1217.
140. Wong AK, Kerkoutian S, Said J, et al. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol 2012; 31: 631-636.
141. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-1231. (Pubitemid 47300423)
142. Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010; 4: 511-522.
143. Kudrin A, Chilvers ER, Ginawi A, et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol 2007; 34: 648-649.
144. Verschueren K, Van Essche E, Verschueren P, et al. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 2007; 26: 1969-1971. (Pubitemid 47516989)
145. Almodó var R, Izquierdo M, Zarco P, et al. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2007; 25: 99-101.
146. Daïen CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48: 883-886.
147. Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148: 262-264.
148. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-869.
149. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568-1574. (Pubitemid 41747058)
150. Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964; 425: 302-308.
151. Chloroquine in the treatment of sarcoidosis. A report from the research committee of the British Tuberculosis Association. Tubercle 1967; 48: 257-272.
152. Leecharoen S, Wangkaew S, Louthrenoo W. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. J Med Assoc Thai 2007; 90: 52-58.
153. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 1999; 140: 3-7. (Pubitemid 29074524)
154. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006; 12: 294-304. (Pubitemid 44285144)
155. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1460-1469. (Pubitemid 34620191)
156. Rebuck AS, Stiller CR, Braude AC, et al. Cyclosporin for pulmonary sarcoidosis. Lancet 1984; 1: 1174. (Pubitemid 14108714)
157. Bomprezzi R, Pati S, Chansakul C, et al. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75: 568-570.
158. Belkhou A, Younsi R, El Bouchti I, et al. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine 2008; 75: 511-512.
159. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-920. (Pubitemid 40733918)
160. Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 2012; 6: 1613-1618.
161. Aksoy S, Dizdar O, Hayran M, et al. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 2009; 50: 357-365.
162. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48: 1307-1312. (Pubitemid 47079357)
163. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824.
164. Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166: 861-872.
165. Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th 1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156: 4952-4960. (Pubitemid 26174485)